| Identification | Back Directory | [Name]
Bufuralol-(t-butyl-d9) hydrochloride
| [CAS]
1173023-51-2 | [Synonyms]
2H9]-Bufuralol
Bufuralol hydrochloride salt
[2H9]-Bufuralol Hydrochloride
2H9]-Bufuralol hydrochloride salt
Bufuralol-(t-butyl-d9) hydrochloride
| [Molecular Formula]
C16H24ClNO2 | [MDL Number]
MFCD09840134 | [MOL File]
1173023-51-2.mol | [Molecular Weight]
297.82 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Methanol: slightly soluble | [form ]
A solid | [InChI]
1S/C16H23NO2.ClH/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4;/h6-9,13,17-18H,5,10H2,1-4H3;1H/i2D3,3D3,4D3; | [InChIKey]
KJBONRGCLLBWCJ-WWMMTMLWSA-N | [SMILES]
Cl.[2H]C([2H])([2H])C(NCC(O)c1cc2cccc(CC)c2o1)(C([2H])([2H])[2H])C([2H])([2H])[2H] |
| Hazard Information | Back Directory | [Description]
Bufuralol-d9 is intended for use as an internal standard for the quantification of bufuralol by GC- or LC-MS. Bufuralol is a non-selective antagonist of β-adrenergic receptors (β-ARs) that also has partial agonist activity. It decreases mean arterial blood pressure and increases abdominal aortic blood flow in anesthetized cats when administered intravenously at doses of 0.3 and 1 mg/kg. Bufuralol is hydroxylated at the 1'' position by the cytochrome P450 (CYP) isoform CYP2D6 and has been used as a substrate to measure CYP2D6 activity. | [Uses]
A b-Adrenergic blocker with peripheral vasodilating activity. Antianginal | [References]
[1] SHIZUO NARIMATSU. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s[J]. Chirality, 2003, 15 4: 333-339. DOI: 10.1002/chir.10212
[2] TH PRINGLE. Pharmacodynamic and pharmacokinetic studies on bufuralol in man.[J]. British journal of clinical pharmacology, 1986, 22 5: 527-534. DOI: 10.1111/j.1365-2125.1986.tb02931.x
[3] L. BLABER. The effects of bufuralol, a beta-adrenoceptor antagonist with predominant beta 2-adrenoceptor agonistic activity, in the cat and the dog.[J]. Journal of Cardiovascular Pharmacology, 1984, 6 1 1: 165-175. DOI: 10.1097/00005344-198401000-00025
[4] MARK J.I. PAINE . Functional High Level Expression of Cytochrome P450 CYP2D6 Using Baculoviral Expression Systems[J]. Archives of biochemistry and biophysics, 1996, 328 1: Pages 143-150. DOI: 10.1006/abbi.1996.0154
[5] NANCY CHEN. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.[J]. Xenobiotica, 2018, 48 6: 637-646. DOI: 10.1080/00498254.2017.1344911 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
| Company Name: |
Pharma Affiliates
|
| Tel: |
172-5066494 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList694812/0_EN.htm |
|